Monday, December 23, 2024
HomeTagsAntibody-drug Conjugates

Antibody-drug Conjugates

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Myricx Bio, a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), announced...

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Tubulis and Bristol Myers Squibb announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs). Through the license agreement, Bristol Myers...

Adcentrx and AvantGen Enter a New Partnership

Adcentrx Therapeutics, a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics